{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:58:13Z","timestamp":1794441493397,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Genome Canada (GC) \/ Genome Quebec","award":["LSARP2017 - 13528"],"award-info":[{"award-number":["LSARP2017 - 13528"]}]},{"name":"Bristol Myers Squibb","award":["LSARP2017 - 13528"],"award-info":[{"award-number":["LSARP2017 - 13528"]}]},{"name":"Genome Canada \/ Genome Quebec","award":["GAPP - 6582"],"award-info":[{"award-number":["GAPP - 6582"]}]},{"name":"RejuvenRx Inc","award":["GAPP - 6582"],"award-info":[{"award-number":["GAPP - 6582"]}]},{"DOI":"10.13039\/501100000024","name":"Canadian Government | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MFE-158159"],"award-info":[{"award-number":["MFE-158159"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In efforts to identify additional therapeutic targets for Acute Myeloid Leukemia (AML), we performed a high-throughput screen that includes 56 primary specimens tested with 10,000 structurally diverse small molecules. One specific hit, called S656 acts as a molecular glue degrader (MGD), that mediates the CRL4-dependent proteolysis of cyclin K. Structurally, S656 features a moiety that binds to the ATP binding site of cyclin-dependent kinases (CDKs), allowing the recruitment of the CDK12-cyclin K complex, along with a binding site for DDB1 bridging the CRL4 complex. Structure activity relationship studies reveal that minimal modifications to the dimethylaniline moiety of S656 improve its cyclin K MGD function over CDK inhibition by promoting DDB1 engagement. This includes full occupation of the DDB1 pocket, preferably with hydrophobic terminal groups, and cation-\u03c0 interaction with Arg928. Additionally, we demonstrate that despite structural diversity, cyclin K degraders exhibit similar functional activity in AML which is distinct from direct CDK12 inhibition.<\/jats:p>","DOI":"10.1038\/s44319-025-00448-y","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:34:58Z","timestamp":1745814898000},"page":"2836-2854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5381-3546","authenticated-orcid":false,"given":"C\u00e9line","family":"Moison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6962-7505","authenticated-orcid":false,"given":"Rodrigo","family":"Mendoza-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne","family":"Gracias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8615-9554","authenticated-orcid":false,"given":"Doris A","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Spinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4593-5104","authenticated-orcid":false,"given":"Simon","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3479-3906","authenticated-orcid":false,"given":"Bounkham","family":"Thavonekham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalila","family":"Chagraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Fortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"MacRae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bonneil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Mayotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Boivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-0331","authenticated-orcid":false,"given":"Pierre","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-1353","authenticated-orcid":false,"given":"Jos\u00e9e","family":"H\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9jean","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0116-8345","authenticated-orcid":false,"given":"Anne","family":"Marinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-7266","authenticated-orcid":false,"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"448_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nchembio.1867","volume":"11","author":"CH Arrowsmith","year":"2015","unstructured":"Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME et al (2015) The promise and peril of chemical probes. Nat Chem Biol 11:536\u2013541","journal-title":"Nat Chem Biol"},{"key":"448_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","volume":"36","author":"I Baccelli","year":"2019","unstructured":"Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella J-F, Corneau S, Mayotte N, Girard S, Frechette M, Blouin-Chagnon V et al (2019) Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia. Cancer Cell 36:84\u201399.e8","journal-title":"Cancer Cell"},{"key":"448_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.10","volume":"7","author":"I Baccelli","year":"2017","unstructured":"Baccelli I, Krosl J, Boucher G, Boivin I, Lavall\u00e9e V-P, H\u00e9bert J, Lemieux S, Marinier A, Sauvageau G (2017) A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens. Blood Cancer J 7:e529","journal-title":"Blood Cancer J"},{"key":"448_CR4","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1101\/gad.1968210","volume":"24","author":"B Bartkowiak","year":"2010","unstructured":"Bartkowiak B, Liu P, Phatnani HP, Fuda NJ, Cooper JJ, Price DH, Adelman K, Lis JT, Greenleaf AL (2010) CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev 24:2303\u20132316","journal-title":"Genes Dev"},{"key":"448_CR5","doi-asserted-by":"publisher","first-page":"e00302","DOI":"10.1128\/MCB.00302-17","volume":"38","author":"T Bertomeu","year":"2018","unstructured":"Bertomeu T, Coulombe-Huntington J, Chatr-Aryamontri A, Bourdages KG, Coyaud E, Raught B, Xia Y, Tyers M (2018) A high-resolution genome-wide CRISPR\/Cas9 viability screen reveals structural features and contextual diversity of the human cell-essential proteome. Mol Cell Biol 38:e00302\u201317","journal-title":"Mol Cell Biol"},{"key":"448_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1947601910369817","volume":"1","author":"K Bettayeb","year":"2010","unstructured":"Bettayeb K, Baunb\u00e6k D, Delehouze C, Loa\u00ebc N, Hole AJ, Baumli S, Endicott JA, Douc-Rasy S, B\u00e9nard J, Oumata N et al (2010) CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer 1:369\u2013380","journal-title":"Genes Cancer"},{"key":"448_CR7","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1101\/gad.16962311","volume":"25","author":"D Blazek","year":"2011","unstructured":"Blazek D, Kohoutek J, Bartholomeeusen K, Johansen E, Hulinkova P, Luo Z, Cimermancic P, Ule J, Peterlin BM (2011) The Cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 25:2158\u20132172","journal-title":"Genes Dev"},{"key":"448_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nchembio.1197","volume":"9","author":"ME Bunnage","year":"2013","unstructured":"Bunnage ME, Chekler ELP, Jones LH (2013) Target validation using chemical probes. Nat Chem Biol 9:195\u2013199","journal-title":"Nat Chem Biol"},{"key":"448_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","volume":"25","author":"GM Burslem","year":"2018","unstructured":"Burslem GM, Smith BE, Lai AC, Jaime-Figueroa S, McQuaid DC, Bondeson DP, Toure M, Dong H, Qian Y, Wang J et al (2018) The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem Biol 25:67\u201377.e3","journal-title":"Cell Chem Biol"},{"key":"448_CR10","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201847592","volume":"20","author":"AP Chirackal Manavalan","year":"2019","unstructured":"Chirackal Manavalan AP, Pilarova K, Kluge M, Bartholomeeusen K, Rajecky M, Oppelt J, Khirsariya P, Paruch K, Krejci L, Friedel CC et al (2019) CDK12 controls G1\/S progression by regulating RNAPII processivity at core DNA replication genes. EMBO Rep 20:e47592","journal-title":"EMBO Rep"},{"key":"448_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A (2020) Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov 10:351\u2013370","journal-title":"Cancer Discov"},{"key":"448_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41375-021-01164-x","volume":"35","author":"DGJ Cucchi","year":"2021","unstructured":"Cucchi DGJ, Polak TB, Ossenkoppele GJ, Uyl-De Groot CA, Cloos J, Zweegman S, Janssen JJWM (2021) Two decades of targeted therapies in acute myeloid leukemia. Leukemia 35:651\u2013660","journal-title":"Leukemia"},{"key":"448_CR13","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1038\/onc.2013.513","volume":"33","author":"C Delehouz\u00e9","year":"2014","unstructured":"Delehouz\u00e9 C, Godl K, Loa\u00ebc N, Bruy\u00e8re C, Desban N, Oumata N, Galons H, Roumeliotis TI, Giannopoulou EG, Grenet J et al (2014) CDK\/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene 33:5675\u20135687","journal-title":"Oncogene"},{"key":"448_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109394","volume":"36","author":"SM Dieter","year":"2021","unstructured":"Dieter SM, Siegl C, Cod\u00f3 PL, Huerta M, Ostermann-Parucha AL, Schulz E, Zowada MK, Martin S, Laaber K, Nowrouzi A et al (2021) Degradation of CCNK\/CDK12 is a druggable vulnerability of colorectal cancer. Cell Rep 36:109394","journal-title":"Cell Rep"},{"key":"448_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447","journal-title":"Blood"},{"key":"448_CR16","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1128\/MCB.18.7.4291","volume":"18","author":"MC Edwards","year":"1998","unstructured":"Edwards MC, Wong C, Elledge SJ (1998) Human cyclin K, a novel RNA polymerase II-associated cyclin possessing both carboxy-terminal domain kinase and Cdk-activating kinase activity. Mol Cell Biol 18:4291\u20134300","journal-title":"Mol Cell Biol"},{"key":"448_CR17","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.celrep.2013.11.020","volume":"5","author":"C Fellmann","year":"2013","unstructured":"Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai DY, Barbosa IAM, Kwon JS, Guan Y et al (2013) An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 5:1704\u20131713","journal-title":"Cell Rep"},{"key":"448_CR18","doi-asserted-by":"publisher","first-page":"9297","DOI":"10.1021\/acs.jmedchem.3c00550","volume":"66","author":"IV Hartung","year":"2023","unstructured":"Hartung IV, Rudolph J, Mader MM, Mulder MPC, Workman P (2023) Expanding chemical probe space: quality criteria for covalent and degrader probes. J Med Chem 66:9297\u20139312","journal-title":"J Med Chem"},{"key":"448_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10637-007-9090-3","volume":"26","author":"EI Heath","year":"2008","unstructured":"Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM (2008) A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26:59\u201365","journal-title":"Invest New Drugs"},{"key":"448_CR20","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1021\/jm0201520","volume":"45","author":"KS Kim","year":"2002","unstructured":"Kim KS, Kimball SD, Misra RN, Rawlins DB, Hunt JT, Xiao H-Y, Lu S, Qian L, Han W-C, Shan W et al (2002) Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 45:3905\u20133927","journal-title":"J Med Chem"},{"key":"448_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1747-1028-7-12","volume":"7","author":"J Kohoutek","year":"2012","unstructured":"Kohoutek J, Blazek D (2012) Cyclin K goes with Cdk12 and Cdk13. Cell Div 7:12","journal-title":"Cell Div"},{"key":"448_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41589-023-01409-z","volume":"20","author":"Z Kozicka","year":"2024","unstructured":"Kozicka Z, Suchyta DJ, Focht V, Kempf G, Petzold G, Jentzsch M, Zou C, Di Genua C, Donovan KA, Coomar S et al (2024) Design principles for cyclin K molecular glue degraders. Nat Chem Biol 20:93\u2013102","journal-title":"Nat Chem Biol"},{"key":"448_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0843-6","volume":"16","author":"W Li","year":"2015","unstructured":"Li W, K\u00f6ster J, Xu H, Chen C-H, Xiao T, Liu JS, Brown M, Liu XS (2015) Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol 16:281","journal-title":"Genome Biol"},{"key":"448_CR24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.59994","volume":"9","author":"L Lv","year":"2020","unstructured":"Lv L, Chen P, Cao L, Li Y, Zeng Z, Cui Y, Wu Q, Li J, Wang J-H, Dong M-Q et al (2020) Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation. eLife 9:e59994","journal-title":"eLife"},{"key":"448_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41589-020-0594-x","volume":"16","author":"C Mayor-Ruiz","year":"2020","unstructured":"Mayor-Ruiz C, Bauer S, Brand M, Kozicka Z, Siklos M, Imrichova H, Kaltheuner IH, Hahn E, Seiler K, Koren A et al (2020) Rational discovery of molecular glue degraders via scalable chemical profiling. Nat Chem Biol 16:1199\u20131207","journal-title":"Nat Chem Biol"},{"key":"448_CR26","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1021\/pr5012608","volume":"14","author":"G M\u00e9dard","year":"2015","unstructured":"M\u00e9dard G, Pachl F, Ruprecht B, Klaeger S, Heinzlmeir S, Helm D, Qiao H, Ku X, Wilhelm M, Kuehne T et al (2015) Optimized chemical proteomics assay for kinase inhibitor profiling. J Proteome Res 14:1574\u20131586","journal-title":"J Proteome Res"},{"key":"448_CR27","doi-asserted-by":"crossref","unstructured":"Misra RN, Xiao H, Kim KS, Lu S, Han W-C, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ et al (2004) N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47:1719\u20131728","DOI":"10.1021\/jm0305568"},{"key":"448_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl4018","volume":"10","author":"C Moison","year":"2024","unstructured":"Moison C, Gracias D, Schmitt J, Girard S, Spinella J-F, Fortier S, Boivin I, Mendoza-Sanchez R, Thavonekham B, MacRae T et al (2024) SF3B1 mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia. Sci Adv 10:eadl4018","journal-title":"Sci Adv"},{"key":"448_CR29","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1182\/bloodadvances.2021005828","volume":"6","author":"C Moison","year":"2022","unstructured":"Moison C, Spinella J-F, Chagraoui J, Lavall\u00e9e V-P, Lehnertz B, Thiollier C, Boivin I, Mayotte N, MacRae T, Marinier A et al (2022) HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2\/M inhibition. Blood Adv 6:4793\u20134806","journal-title":"Blood Adv"},{"key":"448_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbrc.2023.07.028","volume":"676","author":"O Sano","year":"2023","unstructured":"Sano O, Ito M, Saito M, Toita A, Tanaka T, Maezaki H, Araki S, Iwata H (2023) Novel quinazolin-4(3H)-one based Cyclin K degraders regulate alternative polyadenylation activity. Biochem Biophys Res Commun 676:6\u201312","journal-title":"Biochem Biophys Res Commun"},{"key":"448_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/bjh.18843","volume":"202","author":"L Savoy","year":"2023","unstructured":"Savoy L, Long N, Lee H, Chen R, Allen B, Lin H-Y, Tognon C, V Malhotra S, Tyner JW, Zhang H (2023) CDK12\/13 dual inhibitors are potential therapeutics for acute myeloid leukemia. Br J Haematol 202:195\u2013198","journal-title":"Br J Haematol"},{"key":"448_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-020-2374-x","volume":"585","author":"M S\u0142abicki","year":"2020","unstructured":"S\u0142abicki M, Kozicka Z, Petzold G, Li Y-D, Manojkumar M, Bunker RD, Donovan KA, Sievers QL, Koeppel J, Suchyta D et al (2020) The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585:293\u2013297","journal-title":"Nature"},{"key":"448_CR33","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/13543776.2022.2126765","volume":"32","author":"R Tang","year":"2022","unstructured":"Tang R, Liu J, Li S, Zhang J, Yu C, Liu H, Chen F, Lv L, Zhang Q, Yuan K et al (2022) A patent and literature review of CDK12 inhibitors. Expert Opin Ther Pat 32:1055\u20131065","journal-title":"Expert Opin Ther Pat"},{"key":"448_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1021\/acschembio.3c00616","volume":"19","author":"KL Thomas","year":"2024","unstructured":"Thomas KL, Bouguenina H, Miller DSJ, Sialana FJ, Hayhow TG, Choudhary JS, Rossanese OW, Bellenie BR (2024) Degradation by design: new cyclin K degraders from old CDK inhibitors. ACS Chem Biol 19:173\u2013184","journal-title":"ACS Chem Biol"},{"key":"448_CR35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/biomedicines11020641","volume":"11","author":"TM Totiger","year":"2023","unstructured":"Totiger TM, Ghoshal A, Zabroski J, Sondhi A, Bucha S, Jahn J, Feng Y, Taylor J (2023) Targeted therapy development in acute myeloid leukemia. Biomedicines 11:641","journal-title":"Biomedicines"},{"key":"448_CR36","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, Gill S, Harrington WF, Pantel S, Krill-Burger JM et al (2017) Defining a cancer dependency map. Cell 170:564\u2013576.e16","journal-title":"Cell"},{"key":"448_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.1246981","volume":"343","author":"T Wang","year":"2014","unstructured":"Wang T, Wei JJ, Sabatini DM, Lander ES (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science 343:80\u201384","journal-title":"Science"},{"key":"448_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1126\/science.275.5298.343","volume":"275","author":"JN Weinstein","year":"1997","unstructured":"Weinstein JN, Myers TG, O\u2019Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL et al (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343\u2013349","journal-title":"Science"},{"key":"448_CR39","doi-asserted-by":"publisher","first-page":"188842","DOI":"10.1016\/j.bbcan.2022.188842","volume":"1878","author":"W Wu","year":"2023","unstructured":"Wu W, Yu S, Yu X (2023) Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy. Biochim Biophys Acta Rev Cancer 1878:188842","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"448_CR40","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nprot.2017.147","volume":"13","author":"X Zhang","year":"2018","unstructured":"Zhang X, Smits AH, van Tilburg GB, Ovaa H, Huber W, Vermeulen M (2018) Proteome-wide identification of ubiquitin interactions using UbIA-MS. Nat Protoc 13:530\u2013550","journal-title":"Nat Protoc"},{"key":"448_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50642-0","volume":"15","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Li Y, Yang J, Li J, Lin X, Liu T, Yang S, Lin J, Xue S, Yu J et al (2024) Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex. Nat Commun 15:6477","journal-title":"Nat Commun"}],"container-title":["EMBO Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44319-025-00448-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44319-025-00448-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44319-025-00448-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:44:56Z","timestamp":1779122696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44319-025-00448-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,10]]}},"alternative-id":["448"],"URL":"https:\/\/doi.org\/10.1038\/s44319-025-00448-y","relation":{},"ISSN":["1469-3178"],"issn-type":[{"value":"1469-3178","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}